Skip to main content
. 2017 Apr 26;8(28):45898–45917. doi: 10.18632/oncotarget.17438

Figure 3. Activated MAPK and PI3K/AKT signaling confers resistance to anti-EGFR targeted therapy in vitro.

Figure 3

Clonogenic survival of Difi-ΔRAF-1/ERTam (A) and Difi-myr-AKT/ERTam (B) cells cultured in the presence of cetuximab with (gray columns) or without (black columns) 4-OHT for 10 days. Mean colony numbers (+ SD) normalized to medium control from three independent experiments are given. (C, D) Induction of apoptosis by cetuximab in Difi-ΔRAF-1/ERTam (C) and Difi-myr-AKT/ERTam cells (D) with (gray columns) or without (black columns) 4-OHT for 48h. Mean percentages (+ SD) of cells with subgenomic DNA content from three independent experiments are given.